Biotech Values

[DewDiligence]

Roche, BIIB Effectively Terminate Ocrelizumab for RA

[Ocrelizumab is a second-generation variant on Rituxan that targets the CD20 receptor on B-cells. The Ocrelizumab program in lupus was previously halted; the program in RRMS, which is in phase-2, will continue, at least for now.

The Ocrelizumab mishap is good news for Genmab/GSK, whose Arzerra is a direct competitor (#msg-40022740).]

http://www.roche.com/investors/ir_update/inv-update-2010-03-08.htm

›Basel, Switzerland and Cambridge, MA, March 8, 2010

Roche and Biogen Idec decide to suspend Ocrelizumab treatment - Rheumatoid Arthritis development programme on hold

Future of the Ocrelizumab RA clinical programme under evaluation

Roche and Biogen Idec announced today their decision to suspend Ocrelizumab treatment of patients in the Rheumatoid Arthritis (RA) programme. The decision follows the recommendation of the independent Ocrelizumab RA & Lupus Data and Safety Monitoring Board (DSMB) based on their assessment of the studies in RA (SCRIPT, FEATURE, FILM and STAGE) and lupus (BELONG and BEGIN).

The DSMB concluded that the safety risk outweighs the benefits observed in these specific patient populations at this time. The DSMB review detected an infection related safety signal which included serious and opportunistic infections, some of which were fatal.

As previously announced, the FILM study in MTX-naïve RA patients was placed on clinical hold following an assessment of benefit to risk in this specific RA patient population. In addition, the BELONG study in lupus nephritis patients was previously halted due to serious and opportunistic infection signals.

"Patient safety is of the utmost importance in all of our drug development programmes. In light of the DSMB recommendations we have decided to suspend Ocrelizumab treatment in the RA clinical development programme ." said Hal Barron, MD Executive Vice President and Chief Medical Officer at Roche.

The SCRIPT trial in patients who inadequately responded to one or more TNF antagonists and the FILM trial remain blinded [to Roche and BIIB]. A detailed analysis of all of the data will be conducted to help further inform the future of the Ocrelizumab RA clinical programme.

Ocrelizumab is also being evaluated for Relapsing Remitting Multiple Sclerosis (RRMS). The treatment in the Ocrelizumab RRMS Phase II study is ongoing at this time.‹